Advertisement

DARU Journal of Pharmaceutical Sciences

, Volume 27, Issue 2, pp 853–862 | Cite as

Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy

  • Muhammad Asim Farooq
  • Md Aquib
  • Daulat Haleem Khan
  • Zahid Hussain
  • Anam Ahsan
  • Mirza Muhammad Faran Ashraf Baig
  • Dickson Pius Wande
  • Muhammad Masood Ahmad
  • Hafiz Muhammad Ahsan
  • Jiang Jiajie
  • Bo WangEmail author
Review article

Abstract

Background

Disulfiram (DSF) has a long history of being used as a first-line promising therapy for treatment of alcoholism in human. Besides its prominence in the treatment of alcoholism, extensive investigations have been carried out to explore other biomedical and pharmacological effects of DSF. Amongst other biomedical implications, plenty researches have shown evidence of promising anticancer efficacy of this agent for treatment of wide range of cancers such as breast cancer, liver cancer and lung carcinoma.

Methods

Electronic databases, including Google scholar, PubMed and Web of science were searched with the keywords disulfiram, nanoparticles, cancer, drug delivery systems.

Result

Despite its excellent anticancer efficacy, the pharmaceutical significance and clinical applicability of DSF are hampered due to poor stability, low solubility, short plasma half-life, rapid metabolism, and early clearance from systemic circulation. Various attempts have been made to eradicate these issues. Nanotechnology based interventions have gained remarkable recognition in improving pharmacokinetic and pharmacodynamic profile of DSF by improving its stability and avoiding its degradation.

Conclusion

The aim of the present review is to critically analyse all recent developments in designing various nanotechnology-based delivery systems, to ponder their relevance in improving stability, pharmacokinetic and pharmacodynamic profile, and achieving target-specific delivery of this agent to cancer cells to effectively eradicate cancer and abolish its metastasis. Nanotechnology is a novel approach for overcoming such obstacles faced presently, the results obtained so far using different novel drug delivery systems seem to be very promising to increase the stability and half-life of DSF.

Graphical abstract

Nanocrrier mediated drug delivery systems for disulfiram

Keywords

Disulfiram Polymeric nanoparticles Cancer Nanotechnology Drug delivery systems 

Notes

Author’s contributions

Muhammad Asim Farooq designed the review and wrote the manuscript, Md Aquib and Daulat Haleem Khan contributed to searching and data collection, Zahid Hussain critical revision of the manuscript, Anam Ahsan checked the grammar and proofread, Mirza Muhammad Faran Ashraf Baig and Dickson Pius Wande revised the manuscript based on reviewers comments, Muhammad Masood Ahmad and Hafiz Muhammad Ahsan edited the manuscript, Jiang jiajie designed the figures, Bo wang supervised the project. All the authors read and approved the final manuscript.

Compliance with ethical standards

Declaration of interest

The authors state no conflict of interest and have received no funding in preparation of this manuscript.

References

  1. 1.
    Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–83.PubMedGoogle Scholar
  2. 2.
    Cvek B. Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram). Drug Discov Today. 2012;17(9–10):409–12.PubMedGoogle Scholar
  3. 3.
    Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res. 2005;11(3):971–81.PubMedGoogle Scholar
  4. 4.
    Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006;26(3):290–302.PubMedGoogle Scholar
  5. 5.
    Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. ActaPsychiatr. Scand. 1992;86(S369):15–26.Google Scholar
  6. 6.
    Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006;66(21):10425–33.PubMedGoogle Scholar
  7. 7.
    Dalla Pozza E, Donadelli M, Costanzo C, Zaniboni T, Dando I, Franchini M, et al. Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives. Free Radic Biol Med. 2011;50(8):926–33.PubMedGoogle Scholar
  8. 8.
    Kim SK, Kim H, Lee DH, Kim TS, Kim T, Chung C, et al. Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells. PLoS One. 2013;8(10):e78130.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer. 2012;107(9):1488–97.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Cen D, Brayton D, Shahandeh B, Meyskens FL, Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 2004;47(27):6914–20.PubMedGoogle Scholar
  11. 11.
    Liu P, Kumar IS, Brown S, Kannappan V, Tawari PE, Tang JZ, et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer. 2013;109(7):1876–85.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Abu-Serie MM, El-Rashidy FH. In vitro collapsing colon cancer cells by selectivity of disulfiram-loaded charge switchable nanoparticles against cancer stem cells. Recent Pat Anticancer Drug Discov. 2017;12(3):260–71.PubMedGoogle Scholar
  13. 13.
    You SY, Rui W, Chen ST, Chen HC, Liu XW, Huang J, et al. Process of immunogenic cell death caused by disulfiram as the anti-colorectal cancer candidate. Biochem Biophys Res Commun. 2019;513(4):891–7.PubMedGoogle Scholar
  14. 14.
    Duan L, Shen H, Zhao G, Yang R, Cai X, Zhang L, et al. Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells. Biochem Biophys Res Commun. 2014;446(4):1010–6.PubMedGoogle Scholar
  15. 15.
    Sharma V, Verma V, Lal N, Yadav SK, Sarkar S, Mandalapu D, et al. Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor—estrogen receptor β. Mol Carcinog. 2016;55(11):1843–57.PubMedGoogle Scholar
  16. 16.
    Spillier Q, Vertommen D, Ravez S, Marteau R, Thémans Q, Corbet C, et al. Anti-alcohol abuse drug disulfiram inhibits human PHGDH via disruption of its active tetrameric form through a specific cysteine oxidation. Sci Rep. 2019;9(1):4737.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, et al. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009;15(19):6070–8.PubMedGoogle Scholar
  18. 18.
    Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 2011;71(4):333–43.PubMedGoogle Scholar
  19. 19.
    Morrison BW, Doudican NA, Patel KR, Orlow SJ. Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. Melanoma Res. 2010;20(1):11–20.PubMedGoogle Scholar
  20. 20.
    Rae C, Tesson M, Babich JW, Boyd M, Sorensen A, Mairs RJ. The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells. J Nucl Med. 2013;54(6):953–60.PubMedGoogle Scholar
  21. 21.
    Yang Y, Deng Q, Feng X, Sun J. Use of the disulfiram/copper complex for breast cancer chemoprevention in MMTV-erbB2 transgenic mice. Mol Med Rep. 2015;12(1):746–52.PubMedGoogle Scholar
  22. 22.
    Cvek B. Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome. Curr Cancer Drug Tar. 2011;11(3):332–7.Google Scholar
  23. 23.
    Ekinci E, Rohondia S, Khan R, Dou QP. Repurposing Disulfiram as an anti-Cancer agent: updated review on literature and patents. Recent Pat Anticancer Drug Discov. 2019.Google Scholar
  24. 24.
    Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–55.PubMedGoogle Scholar
  25. 25.
    Hu P, Jin L, Baillie TA. Studies on the metabolic activation of Disulfiram in rat. Evidence for electrophilic S-oxygenated metabolites as inhibitors of aldehyde dehydrogenase and precursors of UrinaryN-Acetylcysteine conjugates. J Pharmacol Exp Ther. 1997;281(2):611–7.PubMedGoogle Scholar
  26. 26.
    Wang W, Darling JL. How could a drug used to treat alcoholism also be effective against glioblastoma? Rev Anticancer Ther. 2013;13(3):239–41.Google Scholar
  27. 27.
    Liu P, Wang Z, Brown S, Kannappan V, Tawari PE, Jiang W, et al. Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo. Oncotarget. 2014;5(17):7471.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Löbler M, Rohm HW, Schmitz KP, Johnston AH, Newman TA, Ranjan S, et al. Drug delivery by nanoparticles—facing the obstacles. In4th European Conference of the In Fed for Med and Bio Eng 2009 (pp. 2335-2338). Springer, Berlin. Heidelberg. .Google Scholar
  29. 29.
    Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano. 2013;7(7):5858–69.PubMedGoogle Scholar
  30. 30.
    Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S, et al. Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram. Nanotechnology. 2014;25(12):125102.PubMedGoogle Scholar
  31. 31.
    Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41(7):2971–3010.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Burgess P, Hutt PB, Farokhzad OC, Langer R, Minick S, Zale S. On firm ground: IP protection of therapeutic nanoparticles. Nat Biotechnol. 2010;28(12):1267–70.PubMedGoogle Scholar
  33. 33.
    Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16–20.PubMedGoogle Scholar
  34. 34.
    Khalid M, El-Sawy HS. Polymeric nanoparticles: promising platform for drug delivery. Int J Pharm. 2017;528(1–2):675–91.Google Scholar
  35. 35.
    Lai P, Daear W, Löbenberg R, Prenner EJ. Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly (d, l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surf B Biointerfaces. 2014;118:154–63.PubMedGoogle Scholar
  36. 36.
    Zhuo X, Lei T, Miao L, Chu W, Li X, Luo L, et al. Disulfiram-loaded mixed nanoparticles with high drug-loading and plasma stability by reducing the core crystallinity for intravenous delivery. J Colloid Interface Sci. 2018;529:34–43.PubMedGoogle Scholar
  37. 37.
    Hoda M, Pajaniradje S, Shakya G, Mohankumar K, Rajagopalan R. Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line. Nanomed-Nanotechnol. 2016;12(6):1641–50.Google Scholar
  38. 38.
    Najlah M, Ahmed Z, Iqbal M, Wang Z, Tawari P, Wang W, et al. Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer. Eur J Pharm Biopharm. 2017;112:224–33.PubMedGoogle Scholar
  39. 39.
    He H, Markoutsa E, Li J, Xu P. Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly. Acta Biomater. 2018;68:113–24.PubMedGoogle Scholar
  40. 40.
    Song W, Tang Z, Shen N, Yu H, Jia Y, Zhang D, et al. Combining disulfiram and poly (l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance. J Control Release. 2016;231:94–102.PubMedGoogle Scholar
  41. 41.
    Song W, Tang Z, Lei T, Wen X, Wang G, Zhang D, et al. Stable loading and delivery of disulfiram with mPEG-PLGA/PCL mixed nanoparticles for tumor therapy. Nanomedicine. 2016;12(2):377–86.Google Scholar
  42. 42.
    Fasehee H, Zarrinrad G, Tavangar SM, Ghaffari SH, Faghihi S. The inhibitory effect of disulfiram encapsulated PLGA NPs on tumor growth: different administration routes. Mat Sci Eng C-Mater. 2016;63:587–95.Google Scholar
  43. 43.
    Hanumantha Rao Madala SR, Ali-Osman F, Zhang R, Srivenugopal KS. Brain-and brain tumor-penetrating disulfiram nanoparticles: Sequence of cytotoxic events and efficacy in human glioma cell lines and intracranial xenografts. Oncotarget. 2018;9(3):3459.PubMedGoogle Scholar
  44. 44.
    Fasehee H, Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Faghihi S. A comparative cytotoxic evaluation of disulfiram encapsulated PLGA nanoparticles on MCF-7 cells. Int J Hematol Oncol Stem Cell Res. 11(2):102.Google Scholar
  45. 45.
    Wang Z, Tan J, McConville C, Kannappan V, Tawari PE, Brown J, et al. Poly lactic-co-glycolic acid-controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine. 2017;13(2):641–57.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Tao X, Gou J, Zhang Q, Tan X, Ren T, Yao Q, et al. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core–shell–corona nanoparticles. Biomater Sci. 2018;6(7):1869–81.PubMedGoogle Scholar
  47. 47.
    Peng X, Pan Q, Zhang B, Wan S, Li S, Luo K, et al. Highly stable, coordinated polymeric nanoparticles loading copper (II) diethyldithiocarbamate for combinational chemo/chemodynamic therapy of cancer. Biomacromolecules. 2019;6:2372–83.Google Scholar
  48. 48.
    Miao L, Su J, Zhuo X, Luo L, Kong Y, Gou J, et al. mPEG5k-b-PLGA2k/PCL3. 4k/MCT mixed micelles as carriers of Disulfiram for improving plasma stability and antitumor effect in vivo. Mol. Pharm. 2018;15(4):1556–64.PubMedGoogle Scholar
  49. 49.
    Huo Q, Zhu J, Niu Y, Shi H, Gong Y, Li Y, et al. pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer. Int J Nanomedicine. 2017;12:8631.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Mohammad IS, He W, Yin L. A smart paclitaxel-disulfiram nanococrystals for efficient MDR reversal and enhanced apoptosis. Pharm. Res. 2018;35(4):77.PubMedGoogle Scholar
  51. 51.
    Mohammad IS, Teng C, Chaurasiya B, Yin L, Wu C, He W. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer. Int J Pharm. 2019;557:304–13.PubMedGoogle Scholar
  52. 52.
    Wang C, Yang J, Han H, Chen J, Wang Y, Li Q, et al. Disulfiram-loaded porous PLGA microparticle for inhibiting the proliferation and migration of non-small-cell lung cancer. Int J Nanomedicine. 2017;12:827.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Zhang L, Tian B, Li Y, Lei T, Meng J, Yang L, et al. A copper-mediated disulfiram-loaded pH-triggered PEG-shedding TAT peptide-modified lipid nanocapsules for use in tumor therapy. ACS Appl Mater Interfaces. 2015;7(45):25147–61.PubMedGoogle Scholar
  54. 54.
    Banerjee P, Geng T, Mahanty A, Li T, Zong L, Wang B. Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors. Int J Pharm. 2019;557:374–89.PubMedGoogle Scholar
  55. 55.
    Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8(24):1112–20.PubMedGoogle Scholar
  56. 56.
    Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv. 2010;1(2):323–34.PubMedGoogle Scholar
  57. 57.
    Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563–70.PubMedGoogle Scholar
  58. 58.
    Fasehee H, Dinarvand R, Ghavamzadeh A, Esfandyari-Manesh M, Moradian H, Faghihi S, et al. Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations. J Nanobiotechnol. 2016;14(1):32.Google Scholar
  59. 59.
    Deshmukh AS, Chauhan PN, Noolvi MN, Chaturvedi K, Ganguly K, Shukla SS, et al. Polymeric micelles: basic research to clinical practice. Int J Pharm. 2017;532(1):249–68.PubMedGoogle Scholar
  60. 60.
    Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv. 2013;13:340–415.Google Scholar
  61. 61.
    Yokoyama M. Clinical applications of polymeric micelle carrier systems in chemotherapy and image diagnosis of solid tumors. Med Sci Monit. 2011;3(4):151–8.Google Scholar
  62. 62.
    Farooq MA, Aquib M, Ghayas S, Bushra R, Haleem Khan D, Parveen A, Wang B. Whey protein: a functional and promising material for drug delivery systems recent developments and future prospects POLYM ADVAN TECHNOL. 2019.Google Scholar
  63. 63.
    Farooq MA, Aquib M, Khan DH, Ghayas S, Ahsan A, Ijaz M, et al. Nanocarrier-mediated co-delivery systems for lung cancer therapy: recent developments and prospects. Environ Chem Lett. 2019:1–9.Google Scholar
  64. 64.
    Wong CY, Al-Salami H, Dass CR. Microparticles, microcapsules and microspheres: a review of recent developments and prospects for oral delivery of insulin. Int J Pharm. 2018;537(1–2):223–44.PubMedGoogle Scholar
  65. 65.
    Kesharwani R, Sachan A, Singh S, Patel D. Formulation and evaluation of solid lipid nanoparticle (SLN) based topical gel of etoricoxib. J appl pharm sci. 2016;10:124–31.Google Scholar
  66. 66.
    Amol MP, Rohit RT, Dipak SG, Mohite SK, Magdum CS. A review on solid lipid nanoparticle. Res J of Pharm and Tech. 2016;8(3):218.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Muhammad Asim Farooq
    • 1
  • Md Aquib
    • 1
  • Daulat Haleem Khan
    • 2
  • Zahid Hussain
    • 3
  • Anam Ahsan
    • 4
  • Mirza Muhammad Faran Ashraf Baig
    • 5
  • Dickson Pius Wande
    • 1
  • Muhammad Masood Ahmad
    • 6
  • Hafiz Muhammad Ahsan
    • 7
  • Jiang Jiajie
    • 1
  • Bo Wang
    • 1
    Email author
  1. 1.Department of Pharmaceutics, School of PharmacyChina Pharmaceutical UniversityNanjingPeople’s Republic of China
  2. 2.Department of PharmacyLahore College of Pharmaceutical SciencesLahorePakistan
  3. 3.Department of Pharmaceutics & Pharmaceutical Technology, College of PharmacyUniversity of SharjahSharjahUnited Arab Emirates
  4. 4.College of Animal Science & Veterinary MedicineShanxi Agricultural UniversityTaiguPeople’s Republic of China
  5. 5.State Key Laboratory of Analytical Chemistry for Life Sciences, School of chemistry and Chemical EngineeringNanjing UniversityNanjingChina
  6. 6.Department of Pharmaceutics, College of PharmacyJouf UniversitySakakaKingdom of Saudi Arabia
  7. 7.Department of PharmacologyCMH Institute of Medical SciencesBahawalpurPakistan

Personalised recommendations